Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     

  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Corporate News for May 15, 2020

Zacks Equity Research
·1-min read

  • Shares of Applied DNA Sciences, Inc. APDN surged 71.1% after the DNA technology solutions developer announced that it has received FDA emergency use authorization for its coronavirus diagnostic assay kit.

  • Shares of Immunic, Inc. IMUX soared 5.9% after the clinical-stage biopharmaceutical company reported it received the first regulatory approval from German Health Authority BfArM to initiated a Phase 2 clinical trial of its selective oral DHODH inhibitor, IMU-838, in coronavirus patients.

  • Shares of Cisco Systems, Inc. CSCO rose 4.5% after the company’s third-quarter fiscal 2020 earnings of 79 cents per share beat the Zacks Consensus Estimate by 9.7%.

  • Shares of Virtusa Corporation VRTU lost 20.7% after the company reported fiscal Q4 2020 earnings of $0.41 per share, which missed the Zacks Consensus Estimate of $0.59.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report
 
Applied DNA Sciences Inc (APDN) : Free Stock Analysis Report
 
Virtusa Corporation (VRTU) : Free Stock Analysis Report
 
Immunic, Inc. (IMUX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research